Related Experiment Video
Updated: Jun 26, 2025
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Tri-specific killer engager: unleashing multi-synergic power against cancer
Peeranut Winidmanokul1,2, Aussara Panya1,3, Seiji Okada2
1Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.
Abstract:
Cancer continues to be a global health concern, necessitating innovative solutions for treatment. Tri-specific killer engagers (TriKEs) have emerged as a promising class of immunotherapeutic agents, offering a multifaceted approach to cancer treatment. TriKEs simultaneously engage and activate natural killer (NK) cells while specifically targeting cancer cells, representing an outstanding advancement in immunotherapy. This review explores the generation and mechanisms of TriKEs, highlighting their advantages over other immunotherapies and discussing their potential impact on clinical trials and cancer treatment. TriKEs are composed of three distinct domains, primarily antibody-derived building blocks, linked together by short amino acid sequences. They incorporate critical elements, anti-cluster of differentiation 16 (CD16) and interleukin-15 (IL-15), which activate and enhance NK cell function, together with specific antibody to target each cancer. TriKEs exhibit remarkable potential in preclinical and early clinical studies across various cancer types, making them a versatile tool in cancer immunotherapy. Comparative analyses with other immunotherapies, such as chimeric antigen receptor-T (CAR-T) cell therapy, immune checkpoint inhibitors (ICIs), cytokine therapies, and monoclonal antibodies (mAbs), reveal the unique advantages of TriKEs. They offer a safer pathway for immunotherapy by targeting cancer cells without hyperactivating T cells, reducing off-target effects and complications. The future of TriKEs involves addressing challenges related to dosing, tumor-associated antigen (TAA) expression, and NK cell suppression. Researchers are exploring innovative dosing strategies, enhancing specificity through tumor-specific antigens (TSAs), and combining TriKEs with other therapies for increased efficacy.
Insights
Tri-specific killer engagers (TriKEs) offer a novel immunotherapy approach by activating natural killer (NK) cells to target cancer. This review highlights TriKEs
Area of Science:
- Immunotherapy
- Oncology
- Molecular Biology
Background:
- Cancer remains a significant global health challenge, driving the need for advanced therapeutic strategies.
- Immunotherapy has revolutionized cancer treatment, with natural killer (NK) cell-based approaches showing great promise.
- Tri-specific killer engagers (TriKEs) represent a new frontier in harnessing NK cell activity against cancer.
Purpose of the Study:
- To review the generation and mechanisms of TriKEs.
- To highlight the advantages of TriKEs over existing immunotherapies.
- To discuss the clinical potential and future directions of TriKEs in cancer treatment.
Main Methods:
- TriKEs are engineered molecules comprising antibody-derived domains.
- Key components include anti-CD16 for NK cell engagement and IL-15 for activation.
- A cancer-specific antibody targets tumor cells for precise engagement.
Main Results:
- TriKEs demonstrate significant potential in preclinical and early clinical studies across diverse cancer types.
- Comparative analysis shows TriKEs offer a potentially safer immunotherapy profile than T-cell-based therapies.
- Advantages include targeted cancer cell destruction with reduced T-cell-mediated side effects.
Conclusions:
- TriKEs are a versatile immunotherapeutic platform with broad applicability in oncology.
- Future research focuses on optimizing dosing, enhancing specificity via tumor-specific antigens, and combination therapies.
- TriKEs hold promise for improving clinical outcomes in cancer patients.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...